Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned a consensus recommendation of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $58.20.

A number of research analysts have recently weighed in on the company. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. Finally, HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th.

Insider Buying and Selling

In related news, COO Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94. Following the sale, the chief operating officer now directly owns 26,961 shares in the company, valued at $1,300,059.42. The trade was a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the sale, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. The trade was a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,915 shares of company stock valued at $1,897,920 over the last 90 days. 22.87% of the stock is owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MIRM. State Street Corp grew its position in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Mirum Pharmaceuticals by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after purchasing an additional 17,149 shares during the period. Geode Capital Management LLC grew its holdings in shares of Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after purchasing an additional 29,017 shares in the last quarter. GSA Capital Partners LLP increased its stake in Mirum Pharmaceuticals by 791.7% during the 3rd quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after buying an additional 51,482 shares during the period. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after buying an additional 29,545 shares in the last quarter.

Mirum Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ MIRM opened at $45.22 on Friday. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $54.23. The firm’s 50-day simple moving average is $47.11 and its 200 day simple moving average is $43.46. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -22.39 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. On average, research analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.